Product Images Levetiracetam

levETIRAcetam is a prescription drug that requires Rx-only. It is a product of Lupin Ltd, and packed by RemedyRepack Inc. It comes in a package containing the necessary package insert. Its NDC is 70518-1998-00, and its source NDC is 68180-0115-07. It should be stored at a temperature range of 20-26°C (63-77°F) but could be allowed to range between 15-30°C (59-86°F). No specific expiry date or lot number is provided. This medication shouldn't be within the reach of children.*

This text appears to be a formula for calculating the total daily dose of a medication based on the patient's weight and the daily dose in milligrams per kilogram of body weight. The medication appears to have a concentration of 100 milligrams per milliliter. To use this formula, you would multiply the daily dose in milligrams per kilogram by the patient's weight in kilograms, then divide the result by 100 to get the total daily dose in milliliters.*

This appears to be a formula or equation for calculating a measure called "CLer" which is used to evaluate kidney function in patients. The formula involves calculating based on the patient's age, weight, and serum creatinine levels, with a separate calculation for females. Additionally, the measure is adjusted for body surface area.*

This appears to be a graph representing percentage values on a vertical axis and medication dosage on a horizontal axis. It shows the effectiveness of Levetiracetam at different dosages (1000 mg/day and 3000 mg/day) in treating an unknown condition. However, without additional context or labeling of the axes, it is difficult to determine the full meaning of the information presented in this graph.*

This is a table showing the percentage of patients in different treatment groups including placebo, 1000myjday, and 2000myjday for Levetiracetam. However, without context or further information, the purpose of the study or what the numbers represent is not available.*

This is a tabular representation of patients with various treatment outcomes on Placebo and Levetiracetam. The percentage of patients with successful treatment outcomes for Levetiracetam is higher compared to Placebo. However, it is not clear what the treatment outcomes actually represent without additional context.*

This text represents the percentage of patients who received Placebo and Levetiracetam, along with the respective sample size (N) for each group. The Placebo group consisted of 51 patients and had a percentage of 19.6%, while the Levetiracetam group had 58 patients and a percentage of 43.1%.*

This table shows the percentage of patients who received either placebo or Levetiracetam in a study. The table contains two columns representing the percentage range from 0% to 100% and nine rows representing the percentage values. The data under "100%" is not available. The "Placebo" group had 84 participants, and the "Levetiracetam" group had 79 participants.*